Editors’ Picks, March 2024: Synergy’s Impact on Resistance, New Early Detection Tools, and More
March's picks include how synergy drives drug resistance in AML, new early detection tools, and more.
Progress Against Cancer
March's picks include how synergy drives drug resistance in AML, new early detection tools, and more.
First CAR T-cell therapy approval in chronic lymphocytic leukemia, and Environmental Protection Agency announces a complete ban on asbestos use in manufacturing.
Mirvetuximab soravtansine-gynx was approved for certain ovarian, fallopian tube, and peritoneal cancers. The U.S. Food and Drug Administration (FDA) has approved mirvetuximab soravtansine-gynx (Elaher) for patients with ovarian epithelial, fallopian tube, or peritoneal cancers...
Three patients share their experiences about having Lynch syndrome.
Improvements in medical care have reduced the rate of relapse in acute myeloid leukemia after transplants, helped people live longer, and reduced mortality from other causes, according to large set of data. Older patients...
Researchers are exploring new options for kidney cancer treatments.
The BCR-ABL inhibitor ponatinib was approved for some patients with acute lymphoblastic leukemia. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to ponatinib (Iclusig) in combination with chemotherapy for adult patients...
Modified CAR T-cell therapy shows promise in glioblastoma, and an immunotherapy may soon be available as an injection.
Lisocabtagene maraleucel was approved for some patients with advanced CLL or SLL. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to lisocabtagene maraleucel (Breyanzi) for the treatment of relapsed or refractory...
Tislelizumab-jsgr received its first FDA approval to treat certain esophageal cancers. The U.S. Food and Drug Administration (FDA) has approved tislelizumab-jsgr (Tevimbra) for patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More